EP2046302A2 - Forme pharmaceutique à libération modifiée - Google Patents

Forme pharmaceutique à libération modifiée

Info

Publication number
EP2046302A2
EP2046302A2 EP06851345A EP06851345A EP2046302A2 EP 2046302 A2 EP2046302 A2 EP 2046302A2 EP 06851345 A EP06851345 A EP 06851345A EP 06851345 A EP06851345 A EP 06851345A EP 2046302 A2 EP2046302 A2 EP 2046302A2
Authority
EP
European Patent Office
Prior art keywords
core
dosage form
shell
active ingredient
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06851345A
Other languages
German (de)
English (en)
Inventor
Harry S. Sowden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/107,674 external-priority patent/US8673352B2/en
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority claimed from PCT/US2006/009201 external-priority patent/WO2009023006A2/fr
Publication of EP2046302A2 publication Critical patent/EP2046302A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • This invention relates to dosage forms providing modified release of one or more active ingredients contained therein.
  • Modified release pharmaceutical dosage forms have long been used to optimize drug delivery and enhance patient compliance, especially by reducing the number of doses of medicine the patient must take in a day. In some instances, it is also desirable for a dosage form to deliver more than one drug at different rates or times. Modified release dosage forms should ideally be adaptable so that release rates and profiles can be matched to physiological and chronotherapeutic requirements. Because the onset and duration of the therapeutic efficacy of drugs vary widely, as do their absorption, distribution, metabolism, and elimination, it is often desirable to modify the release of different drugs in different ways, or to have a first dose of drug (active ingredient) immediately released from the dosage form, while a second dose of the same or a different drug is released in a modified, e.g. delayed, pulsatile, repeat action, controlled, sustained, prolonged, extended, or retarded manner. .
  • a dosage form or drug delivery system
  • a controlled rate e.g. sustained, prolonged, extended or retarded release
  • diffusion erosion, and osmosis
  • modified release dosage forms provide a desired blood concentration versus time (pharmacokinetic, or PK) profile for the drug.
  • PK profile for a drug is governed by the rate of absorption of the drug into the blood, and the rate of elimination of the drug from the blood.
  • the drug To be absorbed into the blood (circulatory system), the drug must first be dissolved in the gastrointestinal fluids.
  • controlling the rate of dissolution i.e. drug release from the dosage form
  • the type of PK profile, and correspondingly, the type of dissolution or release profile desired depends on, among other factors, the particular active ingredient and physiological condition being treated.
  • One particularly desirable PK profile is achieved by a dosage form that delivers a delayed release dissolution profile, in which the release of one or more doses of drug from the dosage form is delayed for a pre-determined time after contacting of the dosage form by a liquid medium, such as for example, after ingestion by the patient.
  • the delay period (“lag time") can be followed either by prompt release of the active ingredient ("delayed burst"), or by sustained (prolonged, extended, or retarded) release of the active ingredient ("delayed then sustained”).
  • U.S. Patent No. 5,464,633 discloses delayed-release dosage forms in which an external coating layer was applied by a compression coating process. The coating level ranged from 105 percent to 140 percent of the weight of the core in order to yield product with the desired time delayed profile.
  • One particularly desirable type of delayed release PK profile is obtained from a "pulsatile" release profile, in which for example, a first dose of a first drug is delivered, followed by a delay period ("lag time") during which there is substantially no release of the first drug from the dosage form, followed by either prompt or sustained release of a subsequent dose of the same drug.
  • the first dose is released essentially immediately upon contacting of the dosage form with a liquid medium.
  • the delay period corresponds approximately to the time during which a therapeutic concentration of the first dose is maintained in the blood. Pulsatile delivery systems are particularly useful for applications where a continuous release of drug is not ideal.
  • Examples of this are drugs exhibiting first pass metabolism by the liver, drugs that induce biological tolerance, i.e. the therapeutic effect decreases with continuous presence of the drug at the site of action, and drugs whose efficacy is influenced by circadian rhythms of body functions or diseases.
  • One typical pulsatile dosage form design contains the first dose of drug in an exterior coating, or shell, while subsequent doses of drug are contained in underlying layers of subcoatings, or a central core.
  • PCT Publication No. WO99/62496 discloses a dosage form comprising an immediate-release dose of drug contained within an overcoat applied onto the surface of the semi-permeable membrane of an osmotic dosage form.
  • Patent Nos. 4,857,330 and 4,801,461 disclose dosage forms comprising an exterior drug coat that surrounds a semi-permeable wall, which in turn surrounds an internal compartment containing a second dose of drug, and comprises exit means for connecting the interior of the dosage form with the exterior environment of use. These dosage forms are designed to release drug immediately from the exterior coating, followed by a relatively short delay period, followed by a sustained release of drug from the internal compartment.
  • U.S. Patent No. 4,576,604 discloses an osmotic device (dosage form) comprising a drug compartment surrounded by a wall (coating) having a passageway therein.
  • the wall may comprise an immediate release dose of drug
  • the inner drug compartment may comprise a sustained release dose of drug.
  • U.S. Patent No. 4,449,983 discloses another osmotic device comprising two separately housed drugs that are separately dispensed from the device.
  • the device comprises two compartments, one for each drug, separated by a partition. Each compartment has an Orifice for communicating with the exterior of the device.
  • 5,738,874 discloses a 3-layer pharmaceutical compressed tablet capable of liberating one or more drugs at different release rates, in which an immediate release dose of active may be contained in a compressed coating layer, and in one embodiment, the outer compressed coating layer may function via an erosion mechanism to delay release of a second dose of active ingredient contained in the core.
  • Systems such as these are limited by the amount of drug, which may be incorporated into the exterior coating, or shell, which is in turn limited by the 5 achievable thickness of the exterior coating or shell.
  • U.S. Patent No. 4,865,849 which describes a tablet able to release active substances at successive times, comprising a first layer containing a portion of the active substance, a water soluble or water gellable barrier layer which is interposedo between the first layer and a third layer containing the remaining portion of active substance, and the barrier layer and third layer are housed in an insoluble, impermeable casing.
  • the casing can be applied by various methods such as spraying, compression, or immersion, or the tablet parts can be inserted into a preformed casing.
  • Multilayer compressed tablets in stacked layer configurations5 necessarily require an impermeable partial coating (casing) in order to provide a pulsatile release profile.
  • Publication No. WO00/18447 describes a multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug 5 delivery unit, and substantially enveloped by a scored compressed coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages.
  • a scored extended-release compartment envelops two immediate-release compartments. Active ingredient may be contained in only the extended release compartment, or additionally in the two immediate release compartments.
  • the multiplex drug delivery systems of this example are prepared by press coating the extended-release compartment to substantially envelop the immediate release compartments.
  • Published U.S. patent application 2003/0235616 describes a modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell. The shell comprises at least one opening.
  • the dosage forms comprise at least one active ingredient and at least two cores surrounded by a shell, wherein the shell covers only a portion of at least one core and a fill material is provided over at least one part of the uncovered core.
  • active ingredient which may be present in one or more of the cores, in the shell, or portions or combinations thereof, is released from the dosage form in a modified fashion.
  • the present invention relates to a medicinal dosage form having a first core, a second core, and a shell that is provided over and having a surface conforming or defining a first portion of each core.
  • a fill material is provided over one or more cores having a surface that conform to or define a second portion of at least one core.
  • the fill material that is provided over at least one core is not in contact with any portion of the other core.
  • the fill material and/or the shell material can be substantially devoid of pores having a diameter of 0.5 to 5.0 microns.
  • the first and second cores can be physically separated from one another by a section of the shell.
  • the fill material can extends above the surface level of the shell.
  • the fill material can be a cap that contains an immediate release material, while the shell materia! is a fuse containing insoluble polymeric material.
  • the shell can contain at least one material that is insoluble, semi-permeable, pH-dependent, or erodible in an aqueous environment.
  • the cores can contain a pharmaceutically active ingredient that is released immediately from the dosage form upon contacting of the dosage form with a liquid medium.
  • the shell can provide for delayed, sustained, prolonged, extended, or retarded release of at least one active ingredient contained in one or more cores.
  • the active ingredient in the first core has an immediate release profile and the active ingredient in the second core has a modified release profile.
  • a plurality of beads containing a pharmaceutically active ingredient can be formed as a core within a defined recess of the shell material.
  • the present invention further relates to a medicinal dosage form comprising at least one core containing a pharmaceutical active ingredient and having a cavity.
  • At least one shell portion is provided over the core having a surface that conforms to or defines a first portion of the at least one core.
  • a fuse material is provided in the cavity of the at least one core such that the initial release of pharmaceutical active from the core is governed by the dissolution or erosion profile of the fuse material.
  • the shell portion or portions thereof can be insoluble in a neutral aqueous environment. Alternatively, all of the shell portion or portions thereof are soluble only when exposed to an aqueous medium having a pH greater than about 5.5 or greater than about 8.
  • the cavity can pass entirely through a central region of the core.
  • the present invention also relates to a medicinal dosage form having at least one core containing a pharmaceutical active ingredient wherein a unitary shell portion is provided over the core having a surface conforming to or defining a first portion of the at least one core.
  • a molding plug is provided in the cavity of the at least one core.
  • the molding plug does not contain any pharmaceutical active ingredient.
  • the core can be a compressed tablet having two opposite major faces and the unitary shell portion is provided over both major faces of the compressed tablet.
  • One or more dimples or openings can be provided in a portion of the unitary shell that extends over the molding plug.
  • the core can be in the shape of a torus having an open interior section and a fuse material that is in contact with a surface of the core defining the open interior section.
  • the present invention also relates to a medicinal dosage form having at least two cores, at least one shell portion that is provided over and having a surface conforming or defining a first portion of the cores and at least one fuse material that is provided between and in contact with at least two cores of the dosage form.
  • the fuse is exposed to a dissolution medium only upon dissolution of at least a substantial portion of at least one core in contact therewith.
  • the present invention also relates to methods for preparing such dosage forms.
  • one method for preparing a dosage form includes providing a shell over a first portion of a first core and a first portion of a second core, and providing a fill material over a second portion of at least one core.
  • a dosage form is prepared having a core containing a pharmaceutical active ingredient and having a cavity by providing the core with a fuse material within the cavity of the core and providing at least one shell portion having a surface conforming to a first portion of the at least one core.
  • a dosage form in another embodiment, can be prepared having at least core containing a pharmaceutical active ingredient by providing the core with a mold plug within the cavity of the core and providing a unitary shell portion having a surface conforming to a first portion of the core. Still further, a dosage form can be prepared having at least core containing a pharmaceutical active ingredient by providing at least one fuse material between and in contact with at least two cores of the dosage form and providing a shell portion having a surface conforming or defining a first portion of the core.
  • Figure 1 illustrates an embodiment of the present invention having two cores embedded in shell material and having fill material over both cores.
  • Figure 2 illustrates an alternative embodiment having two cores embedded in shell material and having fill material only over one core.
  • Figure 3 illustrates an embodiment of the present invention in which .fill material is provided between and in contact with two cores.
  • Figure 4 illustrates an alternative embodiment having three cores.
  • dosage form applies to any solid object, semisolid, or liquid composition designed to contain a specific pre-determined amount (dose) of a certain ingredient, for example an active ingredient as defined below.
  • Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like.
  • the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components.
  • the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastrointestinal tract of a human.
  • the present invention is directed to a dosage form for at least one active ingredient having a first core, a second core, and a shell that surrounds a first portion of each core and a fill material that covers a second portion of the first core and/or the second core.
  • the fill material provided over the second portion(s) of each core are separate and distinct from the shell that is otherwise provided over the core. It is possible, however, for the fill material for either the first portion or second portion to overlap with the fill material for the other portion or to be provided in such a way as to expose the underlying core (and/or the subcoating layer).
  • either the first core or the second core is completely surrounded by or embedded in the shell material, while the remaining core is provided with a shell over a first portion and fill material over a second portion thereof.
  • three or more cores are provided in the dosage form wherein none or one or more of the cores is surrounded by the shell material and at least one of the cores is only surrounded over a first portion thereof by shell material with fill material over a second portion.
  • the shell is understood to be a material that is malleable, flowable and conformable such that a shell material, when applied, will have a surface that conforms to the shape of the element (whether a core or another underlying shell) over which it is applied.
  • the core in contrast, has a fixed, generally unitary shape that does not change significantly when introduced or provided in the dosage form.
  • the shell can be molded into a desired shape suitable for holding a core or a plurality of free flowing particles that will constitute the core of the dosage form. Both of the foregoing embodiments will be characterized by having at least some fill material that is a distinct from the shell.
  • Dosage form 10 comprises a first core 11, a second core 12, and a shell 13. Shell 13 surrounds as one or more parts a first portion 14 of first core 11 and a first portion 15 of second core 12. Dosage form 10 can optionally be provided with a subcoating film, described more fully below, over either first core 11, second core 12 or both.
  • Dosage form 10 is shown having fill material 16a for second portion 17 and fill material 16b for second portion 18 as non-overlapping with shell 13 and completely covering second portions 17 and 18, respectively.
  • Non-overlapping means that fill material 16 for each of second portion 17 and second portion 18 covers the respective portions exclusively.
  • Fill material 16 can optionally be level with, lower than, extend above and/or onto the exterior surface of shell 13.
  • Fill material 16a and 16b can be compositionally the same or different.
  • Alternative dosage form 20 comprises a first core 21, a second core 22, and a shell 23.
  • Shell 23 surrounds all of first core 21 and a first portion 25 of second core 22.
  • Fill material 26 covers a second portion 28 of second core 22.
  • Dosage form 20 can optionally be provided with a subcoating film over either first core 21, second core 22 or both.
  • Dosage form 20 is shown having fill material 26a for second portion 28 as non-overlapping with shell 23 and completely covering second portion 28.
  • Fill material 26s can optionally be level with, lower than, extend above and/or onto the exterior surface of shell 23.
  • Dosage form 30 comprises a first core 31, a second core 32, and a shell 33.
  • Shell 33 surrounds as one or more parts a first portion 34 of first core 31 and a first portion 35 of second core 32.
  • Dosage form 30 can optionally be provided with a subcoating film over either first core 31, second core 32 or both.
  • Dosage form 30 is shown having fill material 36a for second portion 37 and fill material 36b for second portion 38 as non- overlapping with shell 33 and completely covering second portions 37 and 38, respectively.
  • the primary difference relative to dosage form 10 is the positioning of first core 31 and second 31 and the incorporation of a fill material 36c between the two cores.
  • Fill material 36a and 36b can optionally be level with, lower than, extend above and/or onto the exterior surface of shell 33.
  • Fill material 36a, 36b and 36c can be compositionally the same or different.
  • An exemplary dosage form 40 is shown in Figure 4.
  • Dosage form 40 comprises a first core 41, a second core 42, third core 49 and a shell 43.
  • Shell 43 surrounds as one or more parts a first portion 44 of first core 41, a first portion 45 of second core 42 and a first portion 50 of third core 49.
  • Fill material 46a covers a 5 second portion 47 of first core 41
  • fill material 46b covers a second portion 48 of second core 42
  • fill material 46c covers a second portion 51 of third core 49.
  • Dosage form 40 can optionally be provided with a subcoating film over any or all of first core 41, second core 42 and third core 49.
  • Fill material 46 can optionally be level with, lower than, extend above and/or onto the exterior surface of shell 43.
  • Fill material i o 46a, 46b and 46c can be compositionally the same or different. Still further embodiments are possible in which two or more cores are provided adjacent to one another or connected via a fill material in a manner similar to dosage form 30.
  • the active ingredient or ingredients are present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired
  • the dosage form comprises at least about 1 weight
  • the dosage form comprises at least about 5 weight percent, say at least about 20 weight percent of a combination of one or more active ingredients.
  • a core comprises a total of at least about 25 weight percent (based on the weight of the core) of one or more active ingredients.
  • the active ingredient or ingredients may be present in the dosage form in any 5 form.
  • the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated. If an active ingredient is in the form of particles, the particles (whether coated or uncoated) typically have an average particle size of about 1-2000 microns.
  • Each core may be any solid form.
  • core refers to a material that is at least partially enveloped or surrounded by another material.
  • a core is a self-contained unitary object, such as a tablet or capsule.
  • a core comprises a solid, for example, a core may be a compressed or molded tablet, hard or soft capsule, suppository, or a confectionery form such as a lozenge, nougat, caramel, fondant, or fat based composition or an osmotic capsule.
  • a core or a portion thereof may be in the form of a semi-solid or a liquid in the finished dosage form.
  • a core may comprise a liquid filled capsule, or a semisolid fondant material.
  • a core comprises a fiowable component, such as a plurality of granules or particles, or a liquid
  • the core preferably additionally comprises an enveloping component, such as a capsule shell, or a molded coating, for containing the fiowable material.
  • the shell or shell portions of the present invention are in direct contact with the enveloping component of the core, which separates the shell from the fiowable component of the core.
  • One or more of the cores is provided with, as by being surrounded or partially covered by, or embedded in, the shell over at least a first portion of said cores.
  • the first and second cores are in physical contact with one another.
  • the term "surrounded”, for purposes of this application, is not meant to imply that all surfaces must be covered by the same shell or other coating material.
  • a core can be partially covered by an overcoated shell material while some of the core is exposed to the external environment. The term is intended to convey the concept of the shell material being provided in a fiowable condition so as to conform to the surface of the underlying element.
  • a portion or section of shell referred herein as the "interior wall" separates one or more cores. The distance between the cores, i.e.
  • the thickness of the interior wall may vary depending upon the desired release characteristics of the dosage form, or practical considerations related to the manufacturing process.
  • the distance between the cores within the dosage form, i.e. the thickness of the interior wall,- is on the order of the thickness of the shell proximal to the core.
  • the thickness of the interior wall may be from about 10% to about 200% of the thickness of a core.
  • the core may have one of a variety of different shapes. Each core may have the same or different physical dimensions, shape, etc. as the other cores.
  • a core has one or more major faces.
  • the core surface typically has opposing upper and lower faces formed by contact with the upper and lower punch faces in the compression machine.
  • the core surface typically further comprises a "belly-band" located between the upper and lower faces, and formed by contact with the die walls in the compression machine.
  • a core may also comprise a multilayer tablet.
  • At least one core is a compressed tablet having a hardness from about 2 to about 30 kp/cm 2 , e.g. from about 6 to about 25 kp/cm 2 .
  • Hardness is a term used in the art to describe the diametral breaking strength of either the core or the coated solid dosage form as measured by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength must be normalized for the area of the break. This normalized value, expressed in kp/cm 2 , is sometimes referred in the art as tablet tensile strength.
  • all the cores in the dosage form comprise a compressed tablet having a hardness from about 2 to about 30 kp/cm 2 , e.g. from about 6 to about 25 kp/cm 2 .
  • Exemplary core shapes that may be employed include tablet shapes formed from compression tooling shapes described by "The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p. 7 (McKeesport, Pa.) (incorporated herein by reference).
  • the cores may be prepared by any suitable method, including for example compression or molding, and depending on the method by which they are made, typically comprise active ingredient and a variety of excipients.
  • suitable excipients include fillers, binders, disintegrants, lubricants, glidants, and the like, as known in the art.
  • a core is made by compression and additionally confers modified release of an active ingredient contained therein, such core preferably further comprises a release-modifying compressible excipient.
  • Suitable fillers for use in making a core or core portion by compression include water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose, sugar-alcohols, which include mannitol, sorbitol, maltitol, xylitol, starch hydrolysates, which include dextrins, and maltodextrins, and the like, water insoluble plastically deforming materials such as microcrystalline cellulose or other cellulosic derivatives, water-insoluble brittle fracture materials such as dicalcium phosphate, tricalcium phosphate and the like and mixtures thereof.
  • water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose
  • sugar-alcohols which include mannitol, sorbitol, maltitol, xylitol
  • starch hydrolysates which include dextrins, and maltod
  • Suitable binders for making a core or core portion by compression include dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pussfulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, sucrose, starches, and the like; and derivatives and mixtures thereof.
  • dry binders such as polyvinyl pyrrolidone
  • Suitable disintegrants for making a core or core portion by compression include sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and the like.
  • Suitable lubricants for making a core or core portion by compression include long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides and waxes.
  • Suitable glidants for making a core or core portion by compression include colloidal silicon dioxide, and the like.
  • Suitable release-modifying excipients for making a core or core portion by compression include swellable erodible hydrophilic materials, insoluble edible materials, pH-dependent polymers, and the like.
  • Suitable swellable erodible hydrophilic materials for use as release- modifying excipients for making a core or core portion by compression include: water swellable cellulose derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof.
  • suitable water swellable cellulose derivatives include sodium carboxymethylcellulpse, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose.
  • suitable polyalkylene glycols include polyethylene glycol.
  • suitable thermoplastic polyalkylene oxides include poly (ethylene oxide).
  • acrylic polymers include potassium methacrylate divinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross- linked acrylic acid homopolymers and copolymers), and the like.
  • suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
  • Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof
  • suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof.
  • suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross- linked carboxymethylcellulose sodium.
  • Suitable insoluble edible materials for use as release-modifying excipients for making a core or core portion by compression include water-insoluble polymers, and low-melting hydrophobic materials.
  • suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
  • Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax-932, Iauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
  • Suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
  • Suitable pH-dependent polymers for use as release-modifying excipients for making a core or core portion by compression include enteric cellulose derivatives, 5 for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyyinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers o such as poly(methacrylic acid, methyl methacrylate) 1 :2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
  • Suitable pharmaceutically acceptable adjuvants for making a core or core portion by compression include, preservatives; high intensity sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavorants; colorants; antioxidants; surfactants; wetting agents; and the like and mixtures thereof.
  • a o dry blending i.e. direct compression
  • wet granulation process may be employed, as known in the art.
  • a dry blending (direct compression) method the active ingredient or ingredients, together with the excipients, are blended in a suitable blender, than transferred directly to a compression machine for pressing into tablets.
  • a wet granulation method the active ingredient or ingredients, appropriate5 excipients, and a solution or dispersion of a wet binder (e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone) are mixed and granulated.
  • a wet binder e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone
  • a dry binder may be included among the excipients, and the mixture may be granulated with water or other suitable solvent.
  • Suitable apparatuses for wet granulation are known. in the art, including low shear, e.g. planetary mixers; high shear mixers; and fluid beds, including rotary fluid beds.
  • the resulting granulated material is dried, and optionally dry-blended with further ingredients, e.g. adjuvants and/or excipients such as for example lubricants, colorants, and the like.
  • the final dry blend is then suitable for compression.
  • Methods for direct compression and wet granulation processes are known in the art, and are described in detail in, for example, Lachman, et al., The Theory and Practice of Industrial Pharmacy. Chapter 11 (3 rd ed. 1986).
  • the dry-blended, or wet granulated, powder mixture is typically compacted into tablets using a rotary compression machine as known in the art, such as for example those commercially available from Fette America Inc., Rockaway, NJ, or Manesty Machines LTD, Liverpool, UK.
  • a rotary compression machine a metered volume of powder is filled into a die cavity, which rotates as part of a "die table" from the filling position to a compaction position where the powder is compacted between an upper and a lower punch to an ejection position where the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary "take-off" bar.
  • At least one core is prepared by the compression methods and apparatus described in copending U.S. Patent 6,767,200, the disclosure of which is incorporated herein by reference.
  • the core is made using a rotary compression module comprising a fill zone, compression zone, and ejection zone in a single apparatus having a double row die construction as shown in Figure 6 of U.S. Patent 6,767,200.
  • the dies of the compression module are preferably filled using the assistance of a vacuum, with filters located in or near each die.
  • Cores made by compression may be single or multi-layer, for example bi-layer, tablets.
  • the core is made up of a plurality of beads that contain at least one active ingredient.
  • a mixture of beads having different active ingredients can be utilized in the dosage form. These beads may be coated with a release modifying agent in order to affect the dissolution characteristics of the active ingredient.
  • the beads may also be coated with a polymer to protect the active ingredient from interaction with other active ingredients, the shell or the fill material.
  • the beads may be placed into the dosage form as a previously compressed unitary mass, or filled as loosely separated beads into a core cavity previously molded into the surrounding shell.
  • the beads can be prepared by coating a drug active onto an inert substrate, e.g., non-pareil seeds, then optionally further coated with a release-modifying coating in conventional fashion using a fluidized bed.
  • the beads can be in the form of granulated particles formed by high shear, spray fluid bed or rotor- granulator processes. Such granulated particles can optionally have a release- modifying coating that can be accomplished in conventional fashion using a fluidized bed.
  • the beads can be prepared as spray dried particles, which then can optionally be further coated with a release-modifying coating in a fluidized bed.
  • the particles typically have an average particle size of about 1 to about 2000 microns.
  • the particles are granules or pellets having an average particle size of about 50 to about 2000 microns, preferably about 50 to about 1000 microns, most preferably about 100 to about 800 microns.
  • the particles may be as described herein, and the particle coating may comprise about 10 to 100 weight percent (based on the weight of the coating) of a film former; optionally up to about 50 weight percent based on the weight of the coating of a pore former; and optionally up to about 30 weight percent of various adjuvants or excipients such as plasticizers etc.
  • the particles may be coated using conventional coating technology which is well known to those skilled in the art including microencapsulation techniques such as coacervation, spray-drying, and fluidized bed coating including tangential spray rotor coating and bottom spray wurster coating. Examples of suitable particle coating methods and materials can be found in United States Patent Nos.
  • Such coated particles may provide controlled release of the active ingredient contained therein in certain embodiments.
  • Suitable film formers for particle coating include, but are not limited to, film- forming water soluble polymers, film-forming proteins, film-forming water insoluble polymers, and film-forming pH-dependent polymers.
  • the film-former for particle coating may be selected from cellulose acetate, ammonio methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and polyethylene oxide, and combinations thereof.
  • suitable film formers may be selected from film forming water insoluble polymers; film forming pH-dependent polymers; and copolymers and combinations thereof.
  • the release- modifying particle coating preferably comprises a pore former.
  • the dosage form comprises multiple shell portions that are compositionally different. Additionally, the shell and fill material will preferably be compositionally and functionally different.
  • the term "compositionally different” means having features that are readily distinguishable by qualitative or quantitative chemical analysis, physical testing, or visual observation.
  • the first and second shell portions may contain different ingredients, or different levels of the same ingredients, or the first and second shell portions may have different physical or chemical properties, different functional properties, or be visually distinct.
  • physical or chemical properties that may be different include hydrophylicity, hydrophobiciry, hygroscopicity, elasticity, plasticity, tensile strength, crystallinity, and density.
  • functional properties which may be different include rate and/or extent of dissolution of the material itself or of an active ingredient therefrom, rate of disintegration of the material, permeability to active ingredients, permeability to water or aqueous media, and the like.
  • visual distinctions include size, shape, topography, or other geometric features, color, hue, opacity, and gloss.
  • one core can be in the form of a solid solution, containing active ingredient in the amorphous state.
  • the dosage form of this invention allows for separation of one active in the amorphous state in one core and one active in the crystalline state in a second core.
  • two active ingredients that are incompatible are separated into their respective cores, and are released simultaneously upon dissolution of the fill material, providing a synergistic therapeutic effect.
  • An example of this would be a combination therapy for the treatment of the human immunodeficiency (HIV) virus, where two protease enzyme inhibitors are combined into one core and one nucleoside enzyme inhibitor is combined into a separate core.
  • Another example includes the combination of one ACE (angiotensin converting enzyme) inhibitor in one core plus another ACE inhibitor in another core for use as therapy for hypertension.
  • the fill material is an immediate release material and one or more sections of the shell are enteric materials or impermeable to neutral aqueous systems at room temperature.
  • the shell can provide for delayed, sustained, prolonged, extended, or retarded release of at least one active ingredient contained in one core, while the fill material is provided over one or more of the remaining cores having an immediate release profile.
  • the shell may also be semi- permeable, where water is allowed to flow into the core portion or portions in one direction.
  • the shell can be impermeable to neutral aqueous systems at room temperature while the fill material can be provided having a delayed, sustained, prolonged, extended, or retarded release of at least one active ingredient from the core, each of the fill materials having the same or different release profiles from one another.
  • the composition of the fill materials may function to modify the release of an active ingredient contained in one or more of the underlying cores.
  • the fill material may function to delay release of an active ingredient from at least one underlying core.
  • the fill material may function to sustain, extend, retard, or prolong the release of at least one active ingredient from at least one core.
  • the fill material comprises release modifying moldable excipients, such as, but not limited to, swellable erodible hydrophilic materials, insoluble edible materials, pH dependent polymers, clays, gelling starches, cross-linked polymers and pharmaceutically acceptable adjuvants described above.
  • the fill material itself may also contain active ingredient.
  • active ingredient will be released immediately from the dosage form upon ingestion, or contacting of the dosage form with a liquid medium.
  • such active ingredient will be released in a controlled, sustained, prolonged, or extended fashion upon ingestion, or contacting of the dosage form with a liquid medium.
  • the fill material can be provided entirely within and through a cavity of an active containing core.
  • This embodiment can be suitable for producing a dosage form having a unitary shell coating that is produced in a single shot injection molding system.
  • the fill material can act as a form of a support or molding plug upon which supports retain the combination within an injection molding cavity and allow shell material to coat the core and molding plug.
  • the molded shell coating can be textured, dimpled or even have further openings to expose the underlying core.
  • unitary is meant to describe a molded shell coated that does not have any seams. The shell in such a case would preferably be 5 dissolvable in an appropriate liquid medium, and further preferably would control the release profile of the active contained in the core.
  • subcoatings are well known in the art and disclosed in, for example, United States Patent Nos. 3,185,626, which is incorporated by reference herein. Any composition suitable for film-coating a tablet may be used as a i o subcoating according to the present invention. Examples of suitable subcoatings are disclosed in United States Patent Nos. 4,683,256, 4,543,370, 4,643,894, 4,828,841, 4,725,441, 4,802,924, 5,630,871, and 6,274,162, which are all incorporated by reference herein. Additional suitable subcoatings include one or more of the following ingredients: cellulose ethers such as hydroxypropylmethylcellulose,
  • the subcoating comprises, based upon the total weight of the subcoating, from about 2 percent to about 8 percent, e.g.
  • the 5 subcoating comprises, based upon the total weight of the subcoating, from about 20 percent to about 50 percent, e.g., from about 25 percent to about 40 percent of HPMC; from about 45 percent to about 75 percent, e.g., from about 50 percent to about 70 percent of maltodextrin; and from about 1 percent to about 10 percent, e.g., from about 5 percent to about 10 percent of PEG 400.
  • the dried subcoating typically is present in an amount, based upon the dry weight of the core, from about 0 percent to about 5 percent.
  • one or more cores e.g. all the cores, are substantially free of subcoating, and the shell or a shell portion is in direct contact with a core surface.
  • the dosage forms of the invention provide modified release of one or more active ingredients contained therein.
  • the active ingredient or ingredients may be found within one or more cores, the shell, the fill materials or portions or combinations thereof.
  • one or more active ingredients are contained in one or more cores. More preferably, at least one active ingredient is contained in each of the cores.
  • modified release means the release of an active ingredient from a dosage form or a portion thereof in other than an immediate release fashion, i.e., other than immediately upon contact of the dosage form or portion thereof with a liquid medium.
  • modified release can be evidenced by modified dissolution characteristics.
  • types of modified release include delayed or controlled.
  • Types of controlled release include pH dependent, prolonged, sustained, extended, retarded, and the like.
  • Modified release profiles that incorporate a delayed release feature include pulsatile, repeat action, and the like.
  • suitable mechanisms for achieving modified release of an active ingredient include diffusion, erosion, surface area control via geometry and/or impermeable barriers, semi-permeable barriers and other known mechanisms known.
  • At least one active ingredient is released from the first core in an immediate release fashion.
  • immediate release means the dissolution characteristics of an active ingredient meets USP specifications for immediate release tablets containing the active ingredient.
  • USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing.
  • the composition of the shell may function to modify the release there through of an active ingredient contained in an underlying core.
  • the shell may function to delay release of an active ingredient from an underlying core.
  • the shell may function to sustain, extend, retard, or prolong the release of at least one active ingredient from the second (distally located) core.
  • the shell comprises a release modifying moldable excipient, such as, but not limited to, swellable erodible hydrophilic materials described above.
  • the dosage form is substantially free (i.e. less than 1 % by weight, preferably less than about 0.1 % by weight, based upon the shell weight) of charge control agents.
  • charge control agents refers to a material having a charge control function, such as those used for electrostatic deposition of coatings onto substrates.
  • charge control agents include metal salicylates, for example zinc salicylate, magnesium salicylate and calcium salicylate; quaternary ammonium salts; benzalkonium chloride; benzethonium chloride; trimethyl tetradecyl ammonium bromide (cetrimide); and cyclodextrins and their adducts.
  • one or more active ingredients contained in the second core are released in a controlled, sustained, prolonged, or extended manner beginning initially upon contact of the dosage for with a liquid medium, without a substantial preceding lag time, e.g. release of at least one active ingredients begins within 30 minutes, e.g. within 15 minutes, say within 10 minutes, of contact of the dosage form with a liquid medium.
  • the shell itself e.g. a portion thereof, or an outer coating thereon may also contain active ingredient.
  • active ingredient will be released immediately from the dosage form upon ingestion, or contacting of the dosage form with a liquid medium.
  • such active ingredient will be released in a controlled, sustained, prolonged, or extended fashion upon ingestion, or contacting of the dosage form with a liquid medium.
  • the cores, the shell, any portions thereof and/or fill material are prepared by molding.
  • the cores, the shell, the fill material or all may be made by solvent-based molding or solvent- free molding.
  • the core or the shell is made from a flowable material optionally comprising active ingredient.
  • the flowable material may be any edible material that is flowable at a temperature between about 37°C and 250 0 C, and that is solid, semi-solid, or can form a gel at a temperature between about -10 0 C and about 35°C.
  • the flowable material When it is in the fluid or flowable state, the flowable material may comprise a dissolved or molten component for solvent-free molding, or optionally a solvent such as for example water or organic solvents, or combinations thereof, for solvent-based molding.
  • the solvent may be partially or substantially removed by drying.
  • solvent-based or solvent-free molding is performed via thermal setting molding using the method and apparatus described in published U.S. patent application 2003-0124183, the disclosure of which is incorporated herein by reference.
  • a core or shell is formed by injecting flowable form into a molding chamber.
  • the flowable material preferably comprises a thermal setting material at a temperature above its melting point but below the decomposition temperature of any active ingredient contained therein.
  • the flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
  • the flowable material may comprise solid particles suspended in a molten matrix, for example a polymer matrix.
  • the flowable material may be completely molten or in the form of a paste.
  • the flowable material may comprise an active ingredient dissolved in a molten material in the case of solvent- free molding.
  • the flowable material may be made by dissolving a solid in a solvent, which solvent is then evaporated after the molding step in the case of solvent-based molding.
  • solvent-based or solvent-free molding is performed by thermal cycle molding using the method and apparatus described in published
  • Thermal cycle molding is performed by injecting a flowable material into a heated molding chamber.
  • the flowable material may comprise active ingredient and a thermoplastic material at a temperature above the set temperature of the thermoplastic material but below the decomposition temperature of active ingredient.
  • the flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
  • the thermal cycle molding module comprises a rotor around which a plurality of mold units are disposed.
  • the thermal cycle molding module includes a reservoir for holding flowable material to make the core.
  • the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • the mold units may comprise center mold assemblies, upper mold assemblies, and lower mold assemblies that mate to form mold cavities having a desired shape, for instance of a core or a shell surrounding one or more cores.
  • Flowable material which is heated to a flowable state in reservoir, is injected into the resulting mold cavities.
  • the temperature of the flowable material is then decreased, hardening the flowable material.
  • the mold assemblies open and eject the finished product.
  • the shell is applied to the dosage form using a thermal cycle molding apparatus of the general type of published U.S. application US 2003-0086973 comprising rotatable center mold assemblies, lower mold assemblies and upper mold assemblies. Cores are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state in reservoir, is injected into the mold cavities created by the closed mold assemblies holding the cores. The temperature of the shell flowable material is then decreased, hardening it • around the cores. The mold assemblies open and eject the finished dosage forms.
  • a thermal cycle molding apparatus of the general type of published U.S. application US 2003-0086973 comprising rotatable center mold assemblies, lower mold assemblies and upper mold assemblies. Cores are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state in reservoir, is injected into the mold cavities created by the closed mold assemblies holding the cores. The temperature of the shell flowable material is then decreased, hardening it • around the cores. The mold assemblies open and eject the finished dosage forms.
  • Shell coating is performed in two steps, each half of the dosage forms being coated separately as shown in the flow diagram published U.S. patent application 2003-
  • the mold assemblies for applying the shell are provided with two or more cavities to accommodate the desired number of cores in the dosage form.
  • a wall preferably made of rubber or metal, separates the cavities and the overall shape of the cavities conform to the shape of the cores.
  • the shell is applied to the dosage form using a zero cycle molding apparatus of the general type of copending application, serial number 10/677,984, filed October 2, 2003 (MCP5018), which is incorporated herein by reference, comprising rotatable center mold assemblies, lower mold assemblies and upper mold assemblies. Cores are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state in reservoir, is injected into the mold cavities created by the closed mold assemblies holding the cores. The mold assemblies open and eject the finished dosage forms. Shell coating is preferably performed in two steps, each half of the dosage forms being coated separately via rotation of the center mold assembly.
  • the mold assemblies for applying the shell are provided with two or more cavities to accommodate the desired number of cores in the dosage form.
  • a wall preferably made of rubber or metal, separates the cavities and the overall shape of the cavities conform to the shape of the cores.
  • the compression module of U.S. Patent 6,767,200 may be employed to make cores.
  • the shell may be made applied to these cores using a thermal cycle molding module as described above.
  • a transfer device may be used to transfer the cores from the compression module to the thermal cycle molding module.
  • Such a transfer device may have the structure shown.published U.S. patent application 2003-0068367. It comprises a plurality of transfer units attached in cantilever fashion to a belt. The transfer device rotates and operates in sync with the compression module and the thermal cycle molding module to which it is coupled. Transfer units comprise retainers for holding cores as they travel around the transfer device,
  • Each transfer unit comprises multiple retainers for holding multiple cores side by side.
  • the distance between the retainers within each transfer unit is adjusted via a cam track/cam follower mechanism as the transfer units move around the transfer device.
  • the cores grouped together for placement in a single dosage form, which have been held within a single transfer unit are properly spaced from one another and ready to be fed into the mold assemblies.
  • the cores may or may not have the same composition, as desired.
  • the cores may comprise a single layer or multiple layers.
  • the compression module may be equipped with multi-tip compression tooling. Three or four-tip tooling, for example, may be used to make three or four cores within one die.
  • the cores may comprise a single layer or multiple layers.
  • the dosage form is made using a modification of the apparatus shown in copending U.S. Application Serial No. 09/966,497, which is incorporated herein by reference.
  • the shell material and fill material are applied to the dosage form by holding the core tablet by one or more prongs.
  • the mold assemblies are in the open position.
  • Center mold assembly 212 as shown in copending U.S. Application Serial No. 09/966,497 as incorporated herein by reference, has received the compressed cores, for example from a compression module according to the invention transferred via a transfer device also according to the invention.
  • the cores are held in the upper mold assembly 214 by one or more prongs surrounded by a gasket, on one portion of the cores.
  • the upper mold assembly closes against the center mold assembly 212.
  • the gasket containing the prongs allows for a portion of the cores to remain uncoated by the shell.
  • flowable material is injected into the mold cavity created by union of the mold assemblies to apply the shell to the cores.
  • the flowable shell material is cooled in the mold cavity.
  • the mold assemblies open with the cores remaining in the upper mold assembly 214.
  • the center mold assembly rotates 180 degrees.
  • the dosage form is made using a modification of the apparatus shown in copending U.S. Application Serial No. 09/966,497.
  • the shell and fill materials are applied to the dosage form by injecting the shell in two steps, followed by injection of the fill materials.
  • the mold assemblies are in the open position.
  • Center mold assembly 212 as shown in copending U.S. Application Serial No. 09/966,497 as incorporated herein by reference, has received the compressed cores, for example from a compression module according to the invention transferred via a transfer device also according to the invention.
  • the upper mold assembly 214 closes against center mold assembly 212.
  • flowable material is injected into the mold cavity created by union of the mold assemblies to apply a shell to the first half of the dosage form.
  • the flowable material is cooled in the mold cavity.
  • the mold assemblies open with the partially coated dosage forms remaining in the upper mold assembly 214.
  • the center mold assembly rotates 180 degrees.
  • the mold assemblies again close and the uncoated portion of the compressed dosage form is covered with flowable material thus forming a shell having an opening aligned with the fill material, in a mold assembly that contains one or more protrusions which prevent a portion of the cores from being covered.
  • the protrusion also contains a nozzle for injecting the fill material.
  • thermoplastic materials for use in or as the flowable material include both water-soluble and water insoluble polymers that are generally linear, not crosslinked, and not strongly hydrogen bonded to adjacent polymer chains.
  • thermoplastic materials include: thermoplastic water-swellable cellulose derivatives, thermoplastic water insoluble cellulose derivatives, thermoplastic vinyl polymers, thermoplastic starches, thermoplastic polyalkylene glycols, thermoplastic polyalkylene oxides, and amorphous sugar-glass, and the like, and derivatives, copolymers, and combinations thereof.
  • suitable thermoplastic water swellable cellulose derivatives include hydroxypropyl cellulose (HPC), hydroxypropylr ⁇ ethyl cellulose (HPMC), methyl cellulose (MC).
  • suitable thermoplastic water insoluble cellulose derivatives include cellulose acetate (CA), ethyl cellulose (EC), cellulose acetate butyrate (CAB), cellulose propionate.
  • thermoplastic vinyl polymers include polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP).
  • PVA polyvinyl alcohol
  • PVP polyvinyl pyrrolidone
  • suitable thermoplastic starches are disclosed for example in U.S. Patent No. 5,427,614.
  • suitable thermoplastic polyalkylene glycols include polyethylene glycol.
  • suitable thermoplastic polyalkylene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
  • Other suitable thermoplastic materials include sugar in the form on an amorphous glass such as that used to make hard candy forms.
  • any film former known in the art is suitable for use in the flowable material.
  • suitable film formers include, but are not limited to, film-forming water-soluble polymers, film-forming proteins, film-forming water insoluble polymers, and film-forming pH ⁇ dependent polymers.
  • the film- former for making the core or shell or portion thereof by molding may be selected from cellulose acetate, ammonium methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and polyethylene oxide, and combinations thereof.
  • Suitable film-forming water soluble polymers include water soluble vinyl polymers such as polyvinyl alcohol (PVA); water soluble polycarbohydrates such as hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, pre-gelatinized starches, and film-forming modified starches; water swellable cellulose derivatives such as hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), hydroxyethylmethylcellulose (HEMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), and hydroxyethylhydroxypropylmethyl cellulose (HEMPMC); water soluble copolymers such as methacrylic acid and methacrylate ester copolymers, polyvinyl alcohol and polyethylene glycol copolymers, polyethylene oxide and polyvinylpyrrolidone copolymers; and derivatives and combinations thereof.
  • Suitable film-forming proteins may be natural or chemically modified, and include gelatin, whey protein, myofibrillar proteins, coagulatable proteins such as albumin, casein, casemates and casein isolates, soy protein and soy protein isolates, zein; and polymers, derivatives and mixtures thereof.
  • Suitable film-forming water insoluble polymers include for example ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
  • Suitable film-forming pH-dependent polymers include enteric cellulose derivatives, such as for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins, such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1: 1, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT L, and the like, and derivatives; salts, copolymers, and combinations thereof.
  • enteric cellulose derivatives such as for example hydroxypropyl methyl
  • HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl groups and from about 7% to about 12% hydroxylpropyl groups.
  • HPMC 2910 is commercially available from the
  • METHOCEL E5 which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20 0 C in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • METHOCEL E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20 0 C in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • METHOCEL E15 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 dps (15 millipascal-seconds) at 20 c C in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • degree of substitution means the average number of substiruent groups attached to an anhydroglucose ring
  • hydroxypropyl molar substitution means the number of moles of hydroxypropyl per mole anhydroglucose.
  • KOLLICOAT polyvinyl alcohol and polyethylene glycol copolymer
  • modified starches include starches that have been modified by crosslinking, chemically modified for improved stability or optimized performance, or physically modified for improved solubility properties or optimized performance.
  • chemically modified starches are well known in the art and typically include those starches that have been chemically treated to cause replacement of some of its hydroxyl groups with either ester or ether groups.
  • Crosslinking as used herein, may occur in modified starches when two hydroxyl
  • pre- gelatinized starches or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility. Suitable modified starches are commercially available from several suppliers such as, for example, A.E. Staley Manufacturing Company, and National Starch & Chemical Company.
  • One suitable film forming modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames PURITY GUM and FILMSET, and derivatives, copolymers, and mixtures thereof.
  • Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100% to about 88% of amylopectin.
  • suitable film forming modified starches include the hydroxypropylated starches, in which some of the hydroxyl groups of the starch have been etherified with hydroxypropyl groups, usually via treatment with propylene oxide.
  • a suitable hydroxypropyl starch that possesses film-forming properties is available from Grain Processing Company under the tradename, PURE-COTE B790.
  • Suitable tapioca dextrins for use as film formers include those available from National Starch & Chemical Company under the tradenames CRYSTAL GUM or K-4484, and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename PURITY GUM 40, and copolymers and mixtures thereof.
  • Any thickener known in the art is suitable for use in the flowable material of the present invention. Examples of such thickeners include but are not limited to hydrocolloids (also referred to herein as gelling polymers), clays, gelling starches, and crystallizable carbohydrates, and derivatives, copolymers and mixtures thereof.
  • hydrocolloids also referred to herein as gelling polymers
  • suitable hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
  • Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
  • suitable gelling starches include acid hydrolyzed starches, and derivatives and mixtures thereof.
  • Additional suitable thickening hydrocolloids include low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30%, such as for example those used to make "gummy" confection forms.
  • Suitable thickeners include crystallizable carbohydrates, and the like, and derivatives and combinations thereof.
  • Suitable crystallizable carbohydrates include the monosaccharides and the oligosaccharides.
  • the aldohexoses e.g., the D and L isomers of allose, altrose, glucose, mannose, gulose, idose, galactose, talose
  • the ketohexoses e.g., the D and L isomers of fructose and sorbose along with their hydrogenated analogs: e.g., glucitol (sorbitol), and mannitol are preferred.
  • the 1,2-disaccharides sucrose and trehalose the 1,4-disaccharides maltose, lactose, and cellobiose, and the 1,6- disaccharides gentiobiose and melibiose, as well as the trisaccharide raff ⁇ nose are preferred along with the isomerized form of sucrose known as isomaltulose and its hydrogenated analog isomalt.
  • Other hydrogenated forms of reducing disaccharides such as maltose and lactose
  • maltitol and lactitol are also preferred.
  • the hydrogenated forms of the aldopentoses e.g., D and L ribose, arabinose, xylose, and lyxose and the hydrogenated forms of the aldotetroses: e.g., D and L erythrose and throse are preferred and are exemplified by xylitol and eryrhritol, respectively.
  • the flowable material comprises gelatin as a gelling polymer.
  • Gelatin is a natural, thermogelling polymer. It is a tasteless and colorless mixture of derived proteins of the albuminous class that is ordinarily soluble in warm water.
  • Two types of gelatin - Type A and Type B — are commonly used.
  • Type A gelatin is a derivative of acid-treated raw materials.
  • Type B gelatin is a o derivative of alkali-treated raw materials.
  • the moisture content of gelatin, as well as its Bloom strength, composition and original gelatin processing conditions, determine its transition temperature between liquid and solid. Bloom is a standard measure of the strength of a gelatin gel, and is roughly correlated with molecular weight.
  • Bloom is defined as the weight in grams required to move a half-inch5 diameter plastic plunger 4 mm into a 6.67% gelatin gel that has been held at 10 0 C for 17 hours.
  • the flowable material is an aqueous solution comprising 20% 275 Bloom pork skin gelatin, 20% 250 Bloom Bone Gelatin, and approximately 60% water.
  • Suitable xanthan gums include those available from CP. Kelco Company o . under the tradenames KELTROL 1000, XANTROL 180, or K9B310.
  • Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
  • Acid-hydrolyzed starch is one type of modified starch that5 results from treating a starch suspension with dilute acid at a temperature below the gelatinization point of the starch. During the acid hydrolysis, the granular form of the starch is maintained in the starch suspension, and the hydrolysis reaction is ended by neutralization, filtration and drying once the desired degree of hydrolysis is reached. As a result, the average molecular size of the starch polymers is reduced. Acid-hydrolyzed starches (also known as “thin boiling starches”) tend to have a much lower hot viscosity than the same native starch as well as a strong tendency to gel when cooled.
  • Gelling starches include those starches that, when combined with water and heated to a temperature sufficient to form a solution, thereafter form a gel upon cooling to a temperature below the gelation point of the starch.
  • gelling starches include, but are not limited to, acid hydrolyzed starches such as that available from Grain Processing Corporation under the tradename PURE-SET B950; hydroxypropyl distarch phosphate such as that available from Grain Processing Corporation under the tradename, PURE-GEL B990, and mixtures thereof.
  • Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • Suitable fatty acid esters include sucrose fatty acid esters, mono-, di-, and tri-glycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
  • suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • suitable waxes include camauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
  • Suitable non-crystallizable carbohydrates include non-crystallizable sugars such as polydextrose, and starch hydrolysates, e.g. glucose syrup, corn syrup, and high fructose corn syrup; and non-crystallizable sugar-alcohols such as maltitol syrup.
  • Suitable solvents for optional use as components of the flowable material for making the core or the shell by molding include water; polar organic solvents such as methanol, ethanol, isopropanol, acetone, and the like; and non-polar organic solvents such as methylene chloride, and the like; and mixtures thereof.
  • the flowable material for making cores or the shell by molding may optionally comprise adjuvants or excipients, which may comprise up to. about 30% by weight of the flowable material.
  • adjuvants or excipients include plasticizers, detackifiers, humectants, surfactants, anti-foaming agents, colorants, flavorants, sweeteners, opacifiers, and the like.
  • Suitable plasticizers for making the core, the shell, or a portion thereof, by molding include, but not be limited to polyethylene glycol; propylene glycol; glycerin; sorbitol; triethyl citrate; tributyl citrate; dibutyl sebecate; vegetable oils such as castor oil, rape oil, olive oil, and sesame oil; surfactants such as Polysorbates, sodium lauryl sulfates, and dioctyl- sodium sulfosuccinates; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums; triacetin; acetyltributyl citrate; diethyloxalate; diethylmalate; diethyl fumarate; diethylmalonate; dioctylphthalate; dibutylsuccinate; glyceroltributyrate; hydrogenated castor oil; fatty acids;
  • the shell typically comprises at least about 30 percent, e.g. at least about 45 percent by weight of a thermal-reversible carrier.
  • the shell may optionally further comprise up to about 55 weight percent of a release-modifying excipient.
  • the shell may optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants and excipients.
  • the release modifying excipient is preferably selected from swellable, erodible hydrophilic materials.
  • the shell typically comprises at least about 10 weight percent, e.g. at least about 12 weight percent or at least about 15 weight percent or at least about 20 weight percent or at least about 25 weight percent of a film-former.
  • the shell may optionally further comprise up to about 55 weight percent of a release- modifying excipient.
  • the shell may again also optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants, and excipients.
  • the term "substantially conformally” means that the inner surface of the shell has peaks and valleys or indentations and protrusions corresponding substantially inversely to the peaks and valleys of the outer surface of the core.
  • the indentations and protrusions typically have a length, width, height or depth in one dimension of greater than 10 microns, say greater than 20 microns, and less than about 30,000 microns, preferably less than about 2000 microns.
  • the total weight of the shell is preferably about 20 percent to about 400 percent of the total weight of the cores.
  • the total weight of the shell is typically from about 50 percent to about 400 percent, e.g. from about 75 percent to about 400 percent, or about 100 percent to about 200 percent of the total weight of the cores.
  • the total weight of the shell is typically from about 20 percent to about 100 percent of the total weight of the cores.
  • the thickness of the shell is important to the release properties of the dosage form.
  • the dosage forms of the invention can be made with precise control over shell thickness, in particular using the zero cycle, thermal cycle or thermal setting injection molding methods and apparatus described above.
  • Typical shell thicknesses that may be employed are about 50 to about 4000 microns. In certain preferred embodiments, the shell has a thickness of less than 800 microns. In embodiments wherein the shell portion is prepared by a solvent-free molding process, the shell portion typically has a thickness of about 500 to about 4000 microns, e.g. about 500 to about 2000 microns, say about 500 to about 800 microns, or about 800 to about 1200 microns. In embodiments wherein the shell portion is prepared by a solvent-based molding process, the shell portion typically has a thickness of less than about 800 microns, e.g. about 100 to about 600 microns, say about 150 to about 400 microns.
  • the dosage form comprises first and second cores and first and second shell portions, and at least one of the shell portions has a thickness of less than about 800 microns, e.g. about 100 to about 600 microns, e.g. about 150 to about 400 microns.
  • the shell is formed by injection molding in a shape having recesses to permit the subsequent incorporation or addition of one or more cores or plurality of coated particles into corresponding recesses. Additional shell material can optionally be provided over the one or more cores or plurality of particles, followed by the provision of fill material over at least a portion of the one or more cores.
  • the fill material and/or shell are substantially devoid of pores.
  • the fill or shell materials are typically substantially free of pores in the diameter range of 0.5 to 5.0 microns, i.e.
  • Pore volume, pore diameter and density may be determined using a Quantachrome Instruments PoreMaster 60 mercury intrusion porosimeter and associated computer software program known as "Porowin.” The procedure is documented in the Quantachrome Instruments PoreMaster Operation Manual.
  • the PoreMaster determines both pore volume and pore diameter of a solid or powder by forced intrusion of a non-wetting liquid (mercury), which involves evacuation of the sample in a sample cell (penetrometer), filling the cell with mercury to surround the sample with mercury, applying pressure to the sample cell by: (i) compressed air (up to 50 psi maximum); and (ii) a hydraulic (oil) pressure generator (up to 60000 psi maximum). Intruded volume is measured by a change in the capacitance as mercury moves from outside the sample into its pores under applied pressure.
  • the flowable material may comprise a thermal-reversible carrier.
  • Suitable thermal- reversible carriers for use in making a core, the shell or both by molding are thermoplastic materials typically having a melting point below about 110 0 C, more preferably between about 20 and about 100 0 C.
  • suitable thermal- reversible carriers for solvent-free molding include thermoplastic polyalkylene glycols, thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches, and the like.
  • Preferred thermal- reversible carriers include polyethylene glycol and polyethylene oxide.
  • Suitable thermoplastic polyalkylene glycols for use as thermal-reversible carriers include polyethylene glycol having molecular weight from about 100 to about 20,000, e.g. from about 100 to about 8,000 Daltons.
  • Suitable thermoplastic polyalkylene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
  • Suitable low-melting hydrophobic materials for use as thermal-reversible carriers include fats, fatty acid esters, phospholipids, and waxes which are solid at room temperature, fat-containing mixtures such as chocolate; and the like.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
  • Suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • suitable waxes that are solid at room temperature include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax.
  • thermoplastic polymers for use as thermal-reversible carriers include thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble polymers, thermoplastic vinyl polymers, thermoplastic starches, and thermoplastic resins, and combinations thereof.
  • Suitable thermoplastic water swellable cellulose derivatives include hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), carboxymethylcellulose (CMC), cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxybutylcellulose (HBC), hydroxyethylcellulose (HEC), hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose, and salts, derivatives, copolymers, and combinations thereof.
  • HPMC hydroxypropylmethyl cellulose
  • MC methyl cellulose
  • CMC carboxymethylcellulose
  • HPC hydroxypropyl cellulose
  • HBC hydroxybutylcellulose
  • HEC hydroxyethylcellulose
  • HPMC hydroxypropy
  • thermoplastic water insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, and the like and derivatives, copolymers, and combinations thereof.
  • Suitable thermoplastic vinyl polymers include polyvinylacetate, polyvinyl alcohol, and polyvinyl pyrrolidone (PVP). Examples of suitable thermoplastic starches for use as thermal-reversible carriers are disclosed for example in U.S. Patent No. 5,427,614.
  • thermoplastic resins for use as thermal- reversible carriers include dammars, mastic, rosin, shellac, sandarac, and glycerol ester of rosin.
  • the thermal-reversible carrier for making a core by molding is selected from polyalkylene glycols, polyalkylene oxides, and combinations thereof.
  • the shell comprises an active ingredient intended to have immediate release from the dosage form, the shell is preferably prepared via solvent-free molding.
  • a thermal-reversible carrier is employed in the flowable material to make the shell, said thermal-reversible carrier preferably selected from polyethylene glycol with weight average molecular weight from about 1450 to about 20000, polyethylene oxide with weight average molecular weight from about 100,000 to about 900,000, and the like.
  • the shell or a shell portion functions as an eroding matrix from which active ingredient dispersed in the shell is liberated by the dissolution of successive layers of the shell surface.
  • the rate of active ingredient release will depend on the dissolution rate of the matrix material in the shell or shell portion.
  • Particularly useful matrix materials for providing surface erosion include those that first absorb liquid, then swell and/or gel prior to dissolving.
  • the shell or shell portion preferably comprises a release modifying moldable excipient comprising a swellable erodible hydrophilic material.
  • the shell or a portion thereof functions as a barrier to prevent release therethrough of an active ingredient contained in an underlying core.
  • active ingredient is typically released from a portion of the core that is not covered by that portion of the shell, for example from a portion of the core in communication with one or more openings in the shell.
  • Such- embodiments advantageously allow for control of the surface area for release of the active ingredient; In certain embodiments for example, the surface area for release of active ingredient can be maintained substantially constant over time.
  • the release of at least one active ingredient follows substantially zero-order kinetics.
  • the shell preferably comprises a modified release composition comprising a water insoluble material, for example a water insoluble polymer.
  • the shell, or a shell portion functions as a delayed release coating to delay release of one or more active ingredients contained in an underlying core.
  • the lag-time for onset of active ingredient release may be governed by erosion of the shell, diffusion of active ingredient through the shell, or a combination thereof.
  • the shell preferably comprises a release modifying moldable excipient comprising a swellable erodible hydrophilic material.
  • Example 1 The following non-limiting example further illustrates the claimed invention.
  • Example 1 The following non-limiting example further illustrates the claimed invention.
  • a dosage form according to the invention providing a double pulse release of ibuprofen is manufactured by a molding process as follows.
  • the double pulse consists of a 200 mg immediate release (IR) ibuprofen followed by a 100 mg burst release of ibuprofen after a predetermined lag time.
  • IR immediate release
  • ibuprofen Core Formulation Preparation of the 200 mg Immediate-Release (IR) Ibuprofen Core Formulation:
  • Ibuprofen and sodium starch glycolate are delumped through a 30 mesh screen and said ingredients are mixed in a 2 qt. twin-shell blender for 5 minutes.
  • Colloidal silicon dioxide is also delumped through a 30 mesh screen and is added to the aforementioned mixture for blending for another 5 minutes.
  • Prescreened (through a 30 mesh screen) ibuprofen and sodium starch glycolate are mixed in a 2 qt. twin shell blender for 5 minutes.
  • a rotary tablet press equipped with round punch and die unit with a diameter of 0.250" is used to make the first core as a tablet.
  • the final blend (from Step 1) is fed into the die of the tablet press and is compressed into a tablet core under 2000 lb/in 2 of operating pressure.
  • the weight of compressed tablet is 213.0 mg, which contains 200.0 mg of ibuprofen.
  • Ibuprofen, microcrystalline cellulose and sodium starch, glycolate are delumped through a 30 mesh screen and said ingredients are mixed in a 2 qt. twin shell blender for 5 minutes.
  • Colloidal silicon dioxide is also delumped through a 30 mesh screen and is added to the aforementioned mixture for blending for another 5 minutes.
  • a rotary tablet press equipped with ' round punch and die unit with a diameter of 0.250" is used to make the second core as a tablet.
  • the final blend (from Step 1) is fed into the die and is compressed into a tablet core under 2000 lb/in 2 of operating pressure.
  • the weight of compressed tablet is 213.0 mg, which contains 100.0 mg of ibuprofen.
  • a polymeric composition suitable for use as a shell for a dosage form and having the formula set forth in Table A below was prepared as follows: Table A: Shell Portion: Formulation of Polymeric Composition
  • the cellulose acetate is added to a beaker containing acetone, triacetin, polyethylene glycol, and water and mixed using a mixer until all powder is dissolved.
  • the mixture is then heated in the 55 0 C water bath to obtain a viscous solution.
  • the carrageenan is then added to the hot solution, and the resulting mixture is heated and stirred until a homogeneous texture is obtained.
  • Part D Preparation of First Fill Material: for Immediate Release
  • the first fill material is prepared for application to the first core portion prepared in Part A.
  • the first fill material comprises red gelatin for immediate release, and is made of the following ingredients: purified water, Opatint Red DD-1761, and 275 Bloom Pork Skin Gelatin added together as a mix of dry gelatin granules.
  • a gelatin slurry is formed from these ingredients and heated to 55°C to melt and dissolve the gelatin.
  • the gelatin solution is held at 55°C for approximately 3 hours (holding times at this temperature can generally range between about 2 and about 16 hours).
  • the solution is then mixed until uniform (about 5 to 15 minutes).
  • the gelatin solution is maintained at 55°C with continuous mixing during its use in the first thermal cycling molding module.
  • the second fill material is prepared for application to the second core portion in Part B.
  • the second fill material is prepared using a dispersion containing 80 parts of hydroxypropyl methylcellulose (HPMC) having a viscosity of about 4000 mPa s in 2% aqueous solution [commercially available from Dow Chemical as METHOCEL K4M]; and 20 parts of Kappa Carrageenan in 471 parts of purified water.
  • the solution has a solids concentration of 17.5%.
  • carrageenan is dispersed in room temperature water with an electric mixer equipped with a propeller style blade to form a liquid carrier.
  • the carrageenan/water dispersion is heated to about 80° C with continued mixing.
  • the HPMC is dispersed in the liquid carrier with the propeller mixer, and mixing continued to maintain the HPMC in a suspended state.
  • a laboratory scale thermal cycle molding unit having an overall caplet shape of dimensions of 0.700" x 0.350" x 0.06", is used to apply the shell portion to the cores.
  • the molding unit comprises a single mold assembly made from an upper mold assembly portion comprising an upper mold cavity, and a lower mold assembly portion comprising a lower mold cavity.
  • the lower mold assembly portion is first cooled to 5°C.
  • the shell material of Part C is introduced into the lower mold cavity.
  • Two separate cores prepared, as described in aforementioned Parts A and B, are immediately inserted into two stations within the cavity.
  • the in-process dosage form is held in the chilled mold for 20 seconds to allow the shell material to harden.
  • the stations separate the two cores within the lower mold cavity by 1 mm.
  • a blank upper mold assembly portion is mated with the lower mold assembly portion.
  • the upper mold cavity comprises a small rod (0.1 mm in diameter x 1 mm in length) attached to its inner surface that contacts one station for one of the cores to allow a portion of the dosage form to remain uncoated.
  • the shell material of Part C is introduced into the upper mold cavity.
  • the lower mold assembly portion which has been maintained at 5 0 C, is mated with the upper mold assembly portion in such a way that the cores of Part A (200 mg ibuprofen tablet) and Part B (100 mg of ibuprofen tablet) is mated with the first core station of the upper mold assembly.
  • the shell material of Part C is introduced into the lower mold cavity and held at 5°C for 30 seconds to harden.
  • the first fill material portion is injected into the upper mold portion and covers the portion of the first core that was not previously covered by the shell.
  • the second fill material portion is simultaneously injected into the upper mold portion and covers the portion of the second core that was not previously covered by the shell.
  • the upper mold is held at 5°C for 60 seconds to allow the first and second fill material portions to harden.
  • the lower mold assembly portion is then removed and the finished dosage form, a molded caplet coated with a shell material and two fill materials, is ejected from the upper mold cavity.
  • the weight gain from the shell material i.e. the difference in weight between the finished dosage form and the core
  • Dosage forms of the invention are made in a continuous process using an apparatus comprising two thermal cycle molding modules linked in series via a transfer device as described at pages 14-16 of copending U.S. Application Serial No. 09/966,939, the disclosure of which is incorporated herein by reference.
  • the dosage forms comprise two cores coated with a shell and a first and second fill portion.
  • the thermal cycle molding modules have the general configuration shown in Figure 3 and pages 27-51 of copending U.S. Application Serial No. 09/966,497, which depicts a thermal cycle molding module 200 comprising a rotor 202 around which a plurality of mold units 204 are disposed.
  • the thermal cycle molding modules include reservoirs 206 (see Figure 4) for holding the shell material, the first fill material, and the second fill material.
  • each thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • 09/966,497 depict the temperature control system 600.
  • the transfer device has the structure shown as 300 in Figure 3 and described on pages 51-57 of copending U.S. Application Serial No. 09/966,414, the disclosure of which is incorporated by reference. It comprises a plurality of transfer units 304 attached in cantilever fashion to a belt 312 as shown in Figures 68 and 69. The transfer device rotates and operates in sync with the thermal cycle molding modules to which it is coupled. Transfer units 304 comprise retainers 330 for holding the cores as they travel around the transfer device.
  • the transfer device transfers the cores aforementioned in Part A and Part B to the second molding module, which applies the shell to the cores.
  • the second thermal cycle molding module is of the type shown in Figure 28A of copending U.S. Application Serial No. 09/966,497.
  • the mold units 204 of the second thermal cycle molding module comprise upper mold assemblies 214, rotatable center mold assemblies 212 and lower mold assemblies 210 as shown in Figure 28C. Cores are continuously transferred to the mold assemblies, which then close over the cores.
  • Center mold assembly 212 as shown in copending U.S. Application Serial No. 09/966,497 as incorporated herein by reference, has received the compressed cores, for example from a compression module according to the invention transferred via a transfer device also according to the invention.
  • the upper mold assembly 214 closes against center mold assembly 212.
  • flowable material is injected into the mold cavity created by union of the mold assemblies to apply a shell from Part C to the first half of the dosage form.
  • the flowable material is cooled in the mold cavity.
  • the mold assemblies open with the partially coated dosage forms remaining in the upper mold assembly 214.
  • the center mold assembly rotates 180 degrees.
  • the mold assemblies again close and the uncoated portion of the compressed dosage form is covered with flowable material thus forming a shell having an opening aligned with the fill material, in a mold assembly that contains one or more protrusions, which prevent a portion of the cores from being covered.
  • the protrusions also contain nozzles for injecting the fill materials.
  • the protrusions retract following the application of the second portion of the shell from Part C, and the flowable fill material from Part D and the fill material from Part E, heated to a flowable state in reservoirs 206, are injected into the uncoated portions of the dosage form, over a portion of the cores from Part A and Part B, forming the fill portions 16 as shown in Figure 1.
  • a molding cycle is completed with setting or hardening of the shell and fill materials on the second half of the compressed dosage form.
  • the mold assemblies again open and the coated compressed dosage form is ejected from the molding module.

Abstract

La présente invention concerne une forme pharmaceutique médicale ayant un premier noyau, un second noyau, et une enveloppe qui entoure une première partie de chaque noyau et un matériau de remplissage qui couvre une seconde partie d'au moins un noyau. Le matériau de remplissage qui couvre au moins un noyau n'est en contact avec aucune partie de l'autre noyau. Les formes pharmaceutiques de l'invention permettent la libération modifiée d'un ou de plusieurs des ingrédients actifs qu'elles contiennent. La présente invention concerne également des procédés de fabrication de ces formes pharmaceutiques médicales.
EP06851345A 2005-04-15 2006-05-08 Forme pharmaceutique à libération modifiée Withdrawn EP2046302A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/107,674 US8673352B2 (en) 2005-04-15 2005-04-15 Modified release dosage form
PCT/US2006/009201 WO2009023006A2 (fr) 2006-05-08 2006-05-08 Forme pharmaceutique à libération modifiée

Publications (1)

Publication Number Publication Date
EP2046302A2 true EP2046302A2 (fr) 2009-04-15

Family

ID=56290792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06851345A Withdrawn EP2046302A2 (fr) 2005-04-15 2006-05-08 Forme pharmaceutique à libération modifiée

Country Status (2)

Country Link
EP (1) EP2046302A2 (fr)
CA (1) CA2604158A1 (fr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009023006A2 *

Also Published As

Publication number Publication date
CA2604158A1 (fr) 2006-10-15

Similar Documents

Publication Publication Date Title
US7416738B2 (en) Modified release dosage form
US8673352B2 (en) Modified release dosage form
EP1545472B1 (fr) Forme galenique a liberation modifiee comprenant deux noyaux et un orifice
CA2500312A1 (fr) Forme dosifiee a liberation modifiee
EP2001451B1 (fr) Enrobages de formes pharmaceutiques non homogenes
US20060233882A1 (en) Osmotic dosage form
EP2007346A1 (fr) Forme pharmaceutique osmotique
EP2046302A2 (fr) Forme pharmaceutique à libération modifiée
WO2009023006A2 (fr) Forme pharmaceutique à libération modifiée
AU2002337772A1 (en) Modified release dosage forms
MXPA05003281A (es) Formas de dosis de liberacion modificada con dos nucleos y una abertura.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20090409

17Q First examination report despatched

Effective date: 20090721

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT PL

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161201